Study data illustrate the potential benefits of controlling serum phosphate, intact parathyroid hormone, and calcium levels in patients with nondialysis-dependent chronic kidney disease.
In a large US study, only half of patients with stage 3, 4, and 5 had undergone PTH retesting at 12, 8, and 4.5 months, respectively, after treatment with vitamin D sterols, in line with KDIGO guidelines.
Study results show that mortality among hemodialysis patients declined from 2006 to 2015 compared with the general Swedish population.
In a study, hemoglobin values did not differ meaningfully among daprodustat users, whether or not they also took one or more phosphate binders.
Fracture prevention efforts should be considered in patients with CKD of any age, according to investigators.
Tenapanor is a first-in-class oral medication that works by blocking the NHE3 transporter in the gastrointestinal tract.
Elevated serum phosphate concentration may be associated with an increased risk for major adverse limb events in patients undergoing hemodialysis.
A study of stable dialysis patients receiving sucroferric oxyhydroxide found no significant changes in hemoglobin, ferritin level, and transferrin saturation.
Achieving serum phosphate levels of 3.5 to 4.5 mg/dL vs 5.0 to 6.0 mg/dL in patients on hemodialysis was associated with less coronary artery calcification, study findings suggest.
In a study of hospitalized patients, increased serum phosphate levels significant increased the risk of acute kidney injury, end-stage renal disease, and death.